Ignite Creation Date:
2024-05-06 @ 5:37 PM
Last Modification Date:
2024-10-26 @ 2:32 PM
Study NCT ID:
NCT05376800
Status:
RECRUITING
Last Update Posted:
2024-04-18
First Post:
2022-05-03
Brief Title:
A Study to Determine How BI 907828 Brigimadlin is Taken up in the Tumor Phase 0 and to Determine the Highest Dose of BI 907828 Brigimadlin That Could be Tolerated Phase 1a in Combination With Radiation Therapy in People With a Brain Tumor Called Glioblastoma
Sponsor:
Boehringer Ingelheim
Organization:
Boehringer Ingelheim
Organization Data
Organization:
Boehringer Ingelheim
Class:
INDUSTRY
Study ID:
1403-0007
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Boehringer Ingelheim
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None